OBSV News and Press, ObsEva SA From 08/01/22

ObsEva ( NASDAQ: OBSV ) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to th...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – August 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) , a biopharmaceutical company developing novel therapies for women’s health, today announced the early retirem...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Joyseulay / Shutterstock.com Pagaya Technologies (NASDAQ: PGY ) stock is rocketing higher on Wednesday despite a lack of news from the artificial intelligence ( AI ) credit analysis company. PGY stoc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: T. Schneider / Shutterstock.com Archer Aviation (NYSE: ACHR ) stock is rising higher on Wednesday after the electric vertical takeoff and landing (eVTOL) company reached an agreement with Honeywell In...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning. It seems that ObsEva is having review is...

Gainers: Blue Water Vaccines ( BWV ) +69% . Leafly Holdings ( LFLY ) +25% . AlloVir ( ALVR ) +23% . Teva Pharmaceutical ( TEVA ) +21% . Nutriband ( NTRB ) +17% . Losers: ObsEva ( OBSV ) -68% . Cassava Scie...

The shares of Swiss biotech ObsEva SA ( NASDAQ: OBSV ) plunged ~78% after the company announced Wednesday it intends to begin a corporate restructuring after the FDA cited issues related to the marketing application of uterine fibroids therapy linzagolix. After the FDA r...

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for...

Swiss biopharmaceutical company ObsEva (NASDAQ:OBSV) on Tuesday said UK's drug regulator approved its antagonist Yselty for the treatment of uterine fibroids in adult women of reproductive age. OBSV stock rose 2.3% to $1.76 in after market trading. Uterine fibroids are non-cancerous...

- Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy - - Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as ...